Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 19th International Workshop on Multiple Myeloma (iwMyeloma) will take place in Miami, FL, on April 10-12, 2026. This workshop will bring together the world’s leading researchers to share their perspectives on how to place the evolving understanding of myeloma in a clinical context and thereby optimize clinical care. iwMyeloma 2026 was supported by BMS (Platinum), Johnson & Johnson (Platinum), AbbVie (Gold), Kite (Gold), AstraZeneca (Silver), Caribou Biosciences (Silver), Legend Biotech (Silver), Pfizer (Silver), Regeneron (Silver), Sanofi (Silver), Genentech (Bronze). Supporters have no influence over the production of the content.
iwMyeloma 2026
The 19th International Workshop on Multiple Myeloma
10–12 April 2026 | Miami, FL
The 19th International Workshop on Multiple Myeloma (iwMyeloma) will take place in Miami, FL, on April 10-12, 2026. This workshop will bring together the world’s leading researchers to share their perspectives on how to place the evolving understanding of myeloma in a clinical context and thereby optimize clinical care. iwMyeloma 2026 was supported by BMS (Platinum), Johnson & Johnson (Platinum), AbbVie (Gold), Kite (Gold), AstraZeneca (Silver), Caribou Biosciences (Silver), Legend Biotech (Silver), Pfizer (Silver), Regeneron (Silver), Sanofi (Silver), Genentech (Bronze). Supporters have no influence over the production of the content.
Roundtable discussions
View all
Genomics and epigenomics 2026: NSD2 or MAF targets for therapy
Genomics and epigenomics 2026: new prognostic factors
Targeting resistance mechanisms and HR biology
Using biological models and single cell analyses to study drugs
Integration of Clinical and Translational Research with the MMRF
Early use of immunotherapy in multiple myeloma
Artificial intelligence in myeloma
Optimizing clinical T-Cell Engaging therapy: CAR-T
Optimizing clinical T-Cell Engaging therapy: antibodies
Genomics and epigenomics 2026: NSD2 or MAF targets for therapy
Mechanistic basis of NSD2 as an oncogene
Yubao Wang NYU Langone , New York City, NY, United States
Apoptotic profiling of t(4;14) MM
Lawrence Boise Emory Winship Cancer Institute, Atlanta, GA, United States
Coming soon
Distinct epigenetic programs of high-risk MM subtypes create targetable dependencies
Benjamin Barwick Winship Cancer Institute of Emory University, Atlanta, GA, United States
Genomics and epigenomics 2026: new prognostic factors
Genetics and epigenetics of early myeloma
Mehmet Samur Dana-Farber Cancer Institute, Boston, MA, United States
Coming soon
Structural variation in HR
Patrick Blaney NYU Langone Health, New York City, NY, United States
Targeting structural variation by their detailed characterization
Brian Walker Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon
Deciphering the biology of bone marrow-independent disease to identify therapeutic vulnerabilities
Niels Wienhold Heidelberg University, Heidelberg, Germany
Coming soon
Targeting resistance mechanisms and HR biology
Epigenetic and epitranscriptomic targets in MM
Felipe Prósper University of Navarra, Navarra, Spain
Epi drivers and drug resistance
Gareth Morgan NYU Langone Health, New York City, NY, United States
Coming soon
Targeting super enhancers
Leif Bergsagel Mayo Clinic, Phoenix, AZ, United States
Coming soon
How to overcome resistance mechanisms to bispecific antibodies in MM
Nizar Bahlis University of Calgary, Calgary, Canada
Coming soon
Targeting p300
Charlotte Pawlyn The Institute of Cancer Research, London, United Kingdom
Coming soon
Using biological models and single cell analyses to study drugs
Modelling resistance to T-cell therapies
Marta Chesi Mayo Clinic, Phoenix, AZ, United States
Coming soon
Using mouse models to find new targets
Marta Larrayoz University of Southampton , Southampton, United Kingdom
A novel, genetically driven vulnerability to mitosis targeting in multiple myeloma
Sarah Gooding Radcliffe Department of Medicine, Oxford, United Kingdom
Coming soon
CSF-1R inhibition & lenalidomide synergy in myeloma post ASCT
Simone Minnie University of California, San Francisco, CA, United States
Immune landscape–driven target discovery in myeloma
Manoj Bhasin Emory University School of Medicine, Atlanta, GA, United States
Coming soon
Integration of clinical and translational research with the MMRF
Molecular correlates of Dara use in RRMM
Christine Ye The University of Texas, MD Anderson Cancer Center, Houston, TX, United States
Coming soon
MM Immune Atlas: insights on NDMM and RRMM
Chaitanya Acharya Multiple Myeloma Research Foundation, Durham, NC, United States
Horizon 2: an adaptive platform trial for high-risk NDMM
Benjamin Derman University of Chicago Medical Center, Chicago, IL, United States
Coming soon
Early use of immunotherapy in multiple myeloma
Use of cell-free DNA (cfDNA) to monitor antigen escape and detect early relapsing disease
Paola Neri University of Calgary, Calgary, Canada
Coming soon
High-risk in the context TecDara
Marc Raab Heidelberg Myeloma Center, Heidelberg, Germany
Coming soon
The role of abbreviated bispecific immunoconsolidation in Newly Diagnosed Myeloma; IMMUNOPLANT Study
Dickran Kazandjian Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon
Cartitude-4: update
Yi Lin Mayo Clinic, Rochester, MN, United States
Coming soon
Isatuximab combinations
Dickran Kazandjian Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon
Alpha emitter targeted therapy
Damian Green Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon
Artificial intelligence in MM
AI in patient management
Ola Landgren Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon
Optimizing clinical T-Cell Engaging therapy: CAR-T
Managing neurotox and ALC expansion
Leo Rasche Würzburg University Hospital, Würzburg, Germany
The role of Arlo-cel
Marc Raab Heidelberg Myeloma Center, Heidelberg, Germany
Coming soon
STEM study
Adam Cohen University of Pennsylvania, Philadelphia, PA, United States
In vivo CAR-T designs
Yi Lin Mayo Clinic, Rochester, MN, United States
Coming soon
The role of anti CD19 binders in CAR-T constructs
Nina Shah University of California, San Francisco, CA, United States
Coming soon
Optimizing clinical T-Cell engaging therapy: antibodies
Tal/Tec and their management
Malin Hultcrantz Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Coming soon
Linvoseltamab
Hans Lee The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Elranatamab
Ola Landgren Sylvester Comprehensive Cancer Center, Miami, FL, United States
Coming soon
Cevostamab
Adam Cohen University of Pennsylvania, Philadelphia, PA, United States
CB-011
Binod Dhakal Medical College of Wisconsin, Milwaukee, WI, United States
Coming soon
ABBV-383
Shaji Kumar Mayo Clinic, Rochester, MN, United States
Coming soon
Trispecifics
Faith Davies NYU Langone Health, New York City, NY, United States
Coming soon
AbbVie's Multiple Myeloma Vision
Annelore Cortoos AbbVie, Philadelphia , PA, United States
Coming soon
